1. Engineered T cell therapy for central nervous system injury.
- Author
-
Gao, Wenqing, Kim, Min Woo, Dykstra, Taitea, Du, Siling, Boskovic, Pavle, Lichti, Cheryl F., Ruiz-Cardozo, Miguel A., Gu, Xingxing, Weizman Shapira, Tal, Rustenhoven, Justin, Molina, Camilo, Smirnov, Igor, Merbl, Yifat, Ray, Wilson Z., and Kipnis, Jonathan
- Abstract
Traumatic injuries to the central nervous system (CNS) afflict millions of individuals worldwide1, yet an effective treatment remains elusive. Following such injuries, the site is populated by a multitude of peripheral immune cells, including T cells, but a comprehensive understanding of the roles and antigen specificity of these endogenous T cells at the injury site has been lacking. This gap has impeded the development of immune-mediated cellular therapies for CNS injuries. Here, using single-cell RNA sequencing, we demonstrated the clonal expansion of mouse and human spinal cord injury-associated T cells and identified that CD4
+ T cell clones in mice exhibit antigen specificity towards self-peptides of myelin and neuronal proteins. Leveraging mRNA-based T cell receptor (TCR) reconstitution, a strategy aimed to minimize potential adverse effects from prolonged activation of self-reactive T cells, we generated engineered transiently autoimmune T cells. These cells demonstrated notable neuroprotective efficacy in CNS injury models, in part by modulating myeloid cells via IFNγ. Our findings elucidate mechanistic insight underlying the neuroprotective function of injury-responsive T cells and pave the way for the future development of T cell therapies for CNS injuries.This study presents a new T cell therapy targeting spinal cord injury, providing a potential new approach for injured CNS. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF